Literature DB >> 29402391

IFN-γ and tumor gangliosides: Implications for the tumor microenvironment.

Barbara Dillinger1, Sarah Ahmadi-Erber1, Manuel Lau1, Markus A Hoelzl1, Friedrich Erhart1, Birgit Juergens1, Dietmar Fuchs2, Andreas Heitger1, Stephan Ladisch3, Alexander M Dohnal4.   

Abstract

Gangliosides shed by tumors into their microenvironment (TME) are immunoinhibitory. Interferon-γ (IFN-γ) may boost antitumor immune responses. Thus we wondered whether IFN-γ would counteract tumor ganglioside-mediated immune suppression. To test this hypothesis, we exposed human monocyte-derived LPS-activated dendritic cells (DC) to IFN-γ and to a highly purified ganglioside, GD1a. DC ganglioside exposure decreased TLR-dependent p38 signaling, explaining the previously observed ganglioside-induced down-modulation of pro-inflammatory surface markers and cytokines. Strikingly, while increasing LPS-dependent DC responses, IFN-γ unexpectedly did not counteract the inhibitory effects of GD1a. Rather, induction of indoleamine 2,3-dioxygenase (IDO1), and expression of STAT1/IRF-1 and programmed cell death ligand (PD-L1), indicated that the immunoinhibitory, not an immune stimulatory, IFN-γ-signaling axis, was active. The combination, IFN-γ and DC ganglioside enrichment, markedly impaired DC stimulatory potential of CD8+ T-cells. We suggest that gangliosides and IFN-γ may act in concert as immunosuppressive mediators in the TME, possibly promoting tumor progression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ganglioside; IFN-γ; Tumor immunosuppression; Tumor microenvironment

Mesh:

Substances:

Year:  2018        PMID: 29402391      PMCID: PMC5826801          DOI: 10.1016/j.cellimm.2018.01.014

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  48 in total

Review 1.  Signal integration between IFNgamma and TLR signalling pathways in macrophages.

Authors:  Kate Schroder; Matthew J Sweet; David A Hume
Journal:  Immunobiology       Date:  2006-07-05       Impact factor: 3.144

Review 2.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

3.  Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma.

Authors:  Johannes E A Wolff; Sabine Wagner; Christiane Reinert; Astrid Gnekow; R-D Kortmann; Joachim Kühl; Stefaan W Van Gool
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

4.  Detection of medulloblastoma and astrocytoma-associated ganglioside GD3 in cerebrospinal fluid.

Authors:  S Ladisch; F Chang; R Li; P Cogen; D Johnson
Journal:  Cancer Lett       Date:  1997-11-25       Impact factor: 8.679

5.  Immunohistochemical staining for ganglioside GD1b as a diagnostic and prognostic marker for primary human brain tumors.

Authors:  T C Comas; T Tai; D Kimmel; B W Scheithauer; P C Burger; D K Pearl; S D Jewell; A J Yates
Journal:  Neuro Oncol       Date:  1999-10       Impact factor: 12.300

6.  Shedding of GD2 ganglioside in patients with retinoblastoma.

Authors:  J Portoukalian; M J David; P Gain; M Richard
Journal:  Int J Cancer       Date:  1993-04-01       Impact factor: 7.396

7.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

Review 8.  How interferon-gamma keeps autoimmune diseases in check.

Authors:  Hilde Kelchtermans; Alfons Billiau; Patrick Matthys
Journal:  Trends Immunol       Date:  2008-09-03       Impact factor: 16.687

9.  Down-regulation of IKKβ expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma.

Authors:  Jakub Mieczkowski; Marta Kocyk; Pawel Nauman; Konrad Gabrusiewicz; Małgorzata Sielska; Piotr Przanowski; Marta Maleszewska; Wenson D Rajan; Dominika Pszczolkowska; Tomasz Tykocki; Wieslawa Grajkowska; Katarzyna Kotulska; Marcin Roszkowski; Boguslaw Kostkiewicz; Bozena Kaminska
Journal:  Oncotarget       Date:  2015-10-20

Review 10.  PD-L1 expression in human cancers and its association with clinical outcomes.

Authors:  Xin Wang; Feifei Teng; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

View more
  4 in total

1.  The Interferon-Gamma Paradox in Cancer.

Authors:  M Raza Zaidi
Journal:  J Interferon Cytokine Res       Date:  2018-11-09       Impact factor: 2.607

2.  Immunomodulatory Effects of Phosphorylated Radix Cyathulae officinalis Polysaccharides in Immunosuppressed Mice.

Authors:  Haibo Feng; Jing Fan; Lang Lin; Yunjie Liu; Dongkun Chai; Jie Yang
Journal:  Molecules       Date:  2019-11-15       Impact factor: 4.411

3.  An ultrasound-driven immune-boosting molecular machine for systemic tumor suppression.

Authors:  Liu Wang; Guangzhe Li; Lei Cao; Yi Dong; Yang Wang; Shisheng Wang; Yueqing Li; Xiuhan Guo; Yi Zhang; Fangfang Sun; Xuemei Du; Jiangan Su; Qing Li; Xiaojun Peng; Kun Shao; Weijie Zhao
Journal:  Sci Adv       Date:  2021-10-20       Impact factor: 14.136

4.  Evaluating the Nutritional and Immune Potentiating Characteristics of Unfermented and Fermented Turmeric Camel Milk in Cyclophosphamide-Induced Immunosuppression in Rats.

Authors:  Thamer Aljutaily
Journal:  Antioxidants (Basel)       Date:  2022-04-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.